Whole exome sequencing reveals a broader variant spectrum of Charcot-Marie-Tooth disease type 2.,Neurogenetics

当前位置： X-MOL 学术 › Neurogenetics › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Whole exome sequencing reveals a broader variant spectrum of Charcot-Marie-Tooth disease type 2.
Neurogenetics ( IF 2.2 ) Pub Date : 2019-12-12 , DOI: 10.1007/s10048-019-00591-4
Shan Lin _{1,

2} , Liu-Qing Xu ₁ , Guo-Rong Xu ₁ , Ling-Ling Guo ₁ , Bi-Juan Lin ₁ , Wan-Jin Chen _{1,

2} , Ning Wang _{1,

2} , Yi Lin _{1,

2} , Jin He _{1,

2}

Affiliation

Charcot-Marie-Tooth disease type 2 (CMT2) is a clinically and genetically heterogeneous inherited neuropathy. Although new causative and disease-associated genes have been identified for CMT2 in recent years, molecular diagnoses are still lacking for a majority of patients. We here studied a cohort of 35 CMT2 patients of Chinese descent, using whole exome sequencing to investigate gene mutations and then explored relationships among genotypes, clinical features, and mitochondrial DNA levels in blood as assessed by droplet digital PCR. We identified pathogenic variants in 57% of CMT2 patients. The most common genetic causes in the cohort were MFN2 mutations. Two patients with typical CMT phenotype and neuromyotonia were detected to harbor compound heterozygous variations in the HINT1 gene. In conclusion, our work supports that the molecular diagnostic rate of CMT2 patients can be increased via whole exome sequencing, and our data suggest that assessment of possible HINT1 mutations should be undertaken for CMT2 patients with neuromyotonia.

更新日期：2019-12-12

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>